These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29356917)

  • 21. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond
    Evans DG; Burghel GJ; Howell SJ; Pugh S; Forde C; Howell A; Lalloo F; Woodward ER
    J Med Genet; 2024 Aug; 61(9):853-855. PubMed ID: 38609177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
    Wang N; Ding H; Liu C; Li X; Wei L; Yu J; Liu M; Ying M; Gao W; Jiang H; Wang Y
    Oncogene; 2015 Oct; 34(40):5198-205. PubMed ID: 25619829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S
    Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    BMC Cancer; 2013 Jun; 13():312. PubMed ID: 23806170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
    Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
    Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
    Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
    Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
    Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
    Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
    BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
    Chen L; Fu F; Huang M; Lv J; Zhang W; Wang C
    Breast Cancer Res Treat; 2020 Apr; 180(3):759-766. PubMed ID: 32072338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
    Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
    Deng H; Chen M; Guo X; Heng J; Xu X; Peng L; Jiang H; Li G; Day JX; Li J; Shan D; Li Y; Zhou Y; Liu B; Dai L; Wang X; Wang J
    Mol Genet Genomic Med; 2019 Jun; 7(6):e672. PubMed ID: 30972954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.